- BBC News - Cancer cell enzymes shown to act as 'good cops' http://t.co/DHX45749NS
- Biowebspin | Events - Biowebspin http://t.co/Z7jC3x16bn via @
- Glasgow scientist wins award for disease detection | Herald Scotland http://t.co/aVzVgWvHmr via @
- Richard Smith: Stratified, personalised, or precision medicine http://t.co/BpLzVvzjt2
- New treatments see blood cancer survival rates up - Health - http://t.co/ss8qL7GgxR: http://t.co/gG0b8Ux6zq
- Antibiotics linked to longer life | Herald Scotland http://t.co/4tet0r5J2g via @
- BBC News - What kind of NHS can Britain afford? http://t.co/d43xAsiqBE
- Comment: Scotland needs free cancer drug access - News - http://t.co/ss8qL7GgxR: http://t.co/fDnlxb4L5X
- BBC News - Scots NHS alert line taking calls from rest of UK http://t.co/w45PdO9NQI
- Scientists hope chemicals found in sea could pave way for treatments | Herald Scotland http://t.co/o95viBbNev via @
- Scientists use skin to create stem cells - Health - http://t.co/5KO1Mcyue1: http://t.co/La1R61GmMW
- RT @ : RT @ : Remember you can catch today's #EIE13 video pitches here: http://t.co/f3m0YS3kWU
- http://t.co/XMwu1VaOKc
- So does the Myriad approach constrain and free innovation in genomics? http://t.co/D9jamXOUB3
- Myriad Genetics stock rises on Angelina Jolie surgery http://t.co/PnK3omGviY via @
Biomedical Catalyst Programme
The £180 million Biomedical Catalyst, announced by David Cameron in December 2011, will see the Medical Research Council and the Technology Strategy Board working together to provide responsive and effective support for the best life science opportunities arising in the UK.
Support through the Biomedical Catalyst is available to UK businesses (SMEs) and academics looking to develop innovative soluions to healthcare challenges either individually or in collaboration.
This joint programme between MRC and TSB will offer three categories of grant:
- Feasiblity Award
- Early Stage Award
- Late Stage Award
The categories are designed to support the maturation of an idea from concept to commercialisation. This will create a pipeline of projects encompassing the early stage exploration of commercial and tecnical potential through to providing utility in the field (which may involve human clinical trials) and development prior to commercialisation. Applicants may apply for the award category most appropriate for their work without having recieved a prior award.
Support will be available for projects arising from any sector or discipline that are aimed at addressing healthcare challenges. Example solutions may include (but are not limited to): regenerative medicine, diagnostics, eHealth, and mHealth Solutions, enabling medical technologies and devices. The Biomedical Catalyst will seek to support those opportunities which demonstrate the highest scientific and commercial potential irrespective of medical area.
The Biomedical Catalyst will operate in response mode and will in essence be "always open". However to assist in processing of applications there will be a key submission and assessment dates which will differ depending ont he category of award and applicant type, please see the links below for further details. The assessment of Early and Late Stage awards will culminate in a panel assessment for both academic and busines led applications enabling funding decisions to be made three times a year.
All applications will be subject to assessment by independant expert reviewers with short-listed applicants for Late Stage Awards bieng interviewed by committee. Applicants for Late Stage Awards are advised to note that should they be successful in bieng invited to interview they should hold the date for the next commitee meetings as these are fixed and non-negotiable. Date will be confirmed when applicants are sent their invitiations to submit a full stage proposal.
Please Note: If your application is led by an academic, you will need to apply on the Medical Research Council Website.
If your application is led by a business you should apply through the Technology Strategy Board Website.
Further Information will be available soon.
